New Delhi: The government panel has dealt a big blow to the country’s largest pharmaceutical company, Pune-based Serum Institute of India (SII). The government panel has recommended against allowing Phase II or III clinical trials of the Kovavax vaccine on children aged 2-17. PTI sources have given this information.
Kovovax not approved in any country – government panel
Serum Institute on Monday applied to DCGI for clinical trials on 920 children in the age group of 2 to 18 years. But according to sources, the expert committee of the Central Drugs Standard Control Organization refused to allow the trial saying that Kovavax has not been approved in any country.
In fact, Serum Institute had announced a license agreement with US-based vaccine company Novavax Inc. in August 2020. The Kovid-19 vaccine prepared by Novavax has been named Kovavax in India. Serum Institute is currently producing ‘Kovshield’ vaccine in the country. ‘Kovavax’ is the second vaccine being developed by it.
What did Adar Poonawalla claim?
Regarding Kovavax, the company’s CEO Adar Poonawalla said, “This vaccine has a great potential to protect our future generations under the age group of 18 years. Its trials are still going on. We hope to have Kovavax this year.” Will be made available to the public by September.